REG - AstraZeneca PLC - Annual Financial Report <Origin Href="QuoteRef">AZN.L</Origin> - Part 20
- Part 20: For the preceding part double click ID:nRSH4027Rs
competitors for chronic hepatitis C may provoke further EU collaboration
and may eventually lead to a change in the overall pricing and
reimbursement landscape.Concurrently, many markets are adopting the use
of Health Technology Assessment (HTA) to provide a rigorous evaluation of
the clinical efficacy of a product, at, or post, launch. HTA evaluations
are also increasingly being used to assess the clinical effect, as well
as cost-effectiveness, of products in a particular health system. This
comes as payers and policymakers attempt to increase efficiencies in the
use and choice of pharmaceutical products.Further information regarding
these pressures is contained in Regulatory requirements and Pricing of
medicines in the Marketplace section from page 13 and page 14,
respectively.
- More to follow, for following part double click ID:nRSH4027RuRecent news on AstraZeneca
See all newsREG - AstraZeneca PLC - Tozorakimab met OBERON/TITANIA primary endpoints
AnnouncementREG - AstraZeneca PLC - Notification of Admission of Shares
AnnouncementREG - AstraZeneca PLC - Imfinzi approved in EU for early gastric cancer
AnnouncementREG - AstraZeneca PLC - Notice of AGM
AnnouncementRCS - Redx Pharma Limited - RXC008 Receives US FDA Fast Track Designation
Announcement